<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791358</url>
  </required_header>
  <id_info>
    <org_study_id>RAI 20-1001</org_study_id>
    <nct_id>NCT04791358</nct_id>
  </id_info>
  <brief_title>Decision Impact Trial of KidneyIntelX</brief_title>
  <official_title>A Prospective Decision Impact Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renalytix AI, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renalytix AI, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the&#xD;
      clinical management of type 2 diabetes patients identified as increased risk for rapid kidney&#xD;
      function decline within 5-years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion (target: 20% increase from prior measurements) of visits in which each participant achieves target blood pressure of &lt;140/90 mmHg (as per the NKF CKD management guidelines).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients that achieve individualized target of HbA1c.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACEi/ARB</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients recently treated with statins and or angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SGLT2/ GLP1</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients recently treated with SGLT2 inhibitors or GLP1 agonists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine albumin to creatinine ratio</measure>
    <time_frame>12 Months</time_frame>
    <description>In those with baseline albuminuria, proportion (target: 20%) of patients achieving a 30% decrease in their urine albumin to creatinine ratio from averaged pre-enrollment values to average post-enrollment values through 1 year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Referrals</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients referred/managed by a dietician, diabetologist, or nephrologist.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>KidneyIntelX</intervention_name>
    <description>KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Type 2 diabetes and existing chronic kidney disease stages 1-3.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  23 years of age or older.&#xD;
&#xD;
          -  Clinical history of confirmed type 2 diabetes.&#xD;
&#xD;
          -  Evidence of DKD Stages 1-3:&#xD;
&#xD;
          -  Baseline eGFR of 30-60 ml/min/1.73m2 (confirmed 3 months apart with at least one value&#xD;
             within 1 year prior to enrollment)&#xD;
&#xD;
          -  Individuals with eGFR ≥60 ml/min/1.73m2 and albuminuria (UACR ≥30mg/g)&#xD;
&#xD;
          -  All patients will have a HbA1c, eGFR, urine albumin and urine creatinine, eGFR,&#xD;
             available from within 12 months of enrollment (to be obtained if not clinically&#xD;
             available prior).&#xD;
&#xD;
          -  The subject must be able to comprehend and sign an approved informed consent form and&#xD;
             other applicable study documents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with eGFR &lt;30 or ≥ 60 ml/min/1.73m2 without albuminuria.&#xD;
&#xD;
          -  Patients with ESRD or on renal recovery treatments at time of enrollment.&#xD;
&#xD;
          -  Patients who are pregnant at the time of enrollment.&#xD;
&#xD;
          -  Patients who are currently hospitalized.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger Tun</last_name>
    <phone>646-397-3970</phone>
    <phone_ext>106</phone_ext>
    <email>rtun@renalytixai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Office of Dr. Lev Barats</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

